Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ImmuneXcite Inc.

Next-gen cancer immunotherapy

This article was originally published in Start Up

Executive Summary

Cancer immunotherapy technologies based on T cells, such as immune checkpoint inhibitors, direct the immune system to attack malignant cells. ImmuneXcite Inc. is developing a novel cancer immunotherapy platform technology that entices another more abundant immune cell type, neutrophils, to engulf and destroy malignant cells as well as activate T cells, an approach that could also prove useful in combination with T-cell-based immunotherapeutic approaches.

You may also be interested in...

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis

As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.

Start-Up Spotlight: Peripal, Easing Peritoneal Dialysis For ESRD

Peritoneal dialysis (PD) can allow renal patients to dialyze at home, but connecting one’s catheter to the equipment carries an infection risk and is too tricky for some patients. Swiss startup Peripal AG, which closed a Series A1 round with prominent Swiss investors in July, is betting that its patient-aid device will make PD easier and safer while cutting costs for medical systems.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts